Our unique process, paired withinnovation and continued improvement and evolution, puts us at the forefront.
Humacyte Commences Phase II Vascular Trauma Trial
Humacyte Appoints Doug Blankenship as Chief Financial Officer
U.S. Kidney Patients Help Drive Care Innovation Patient insights Accelerate Research and Development
Bioengineered Blood Vessel Aims to Revolutionize Dialysis Access
From lower costs to fewer operations, HAVs may offer critical benefits.
With each year, we’ve movedcloser to lifesaving treatments.